Breaking News, Collaborations & Alliances

Cytovance Signs Service Agreement with GT Biopharma

GT affirms manufacturing timeline for lead investigational asset GTB-3650.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GT Biopharma, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company’s proprietary natural killer (NK) cell engager, TriKE platform, entered into a settlement and investment agreement with its contract manufacturing partner, Cytovance Biologics. The agreement covers all work required to facilitate the registration of an investigational new drug (IND) filing with the U.S. FDA of its lead investigational asset GTB-3650. GTB-3650 is the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters